Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital271 Beijing Tiantan Hospital219 Cancer Institute and Hospital, Chinese Academy of Medical Sciences205 AstraZeneca191 Peking University People's Hospital166
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Beijing

5576 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
NCT07306585Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugHC022
HC Biopharma Inc.
Phase 1
32
Beijing
2025-12-30
Not yet open
The Correlation Between Obstructive Sleep Apnea-Related Nocturnal Hypoxemia Parameters and Coronary Microvascular Dysfunction: A Prospective Cohort Study (SLEEP-CMD)
NCT07315399OSA - Obstructive Sleep Apnea, Coronary Microvascular Dysfunction (CMD), Coronary Artery Disease (CAD)
Beijing Anzhen Hospital
Observational
560
Beijing
2025-12-30
Recruiting
Beijing Tiantan Hospital
Not applicable
1,170
Beijing
2025-12-30
Recruiting
Beijing Tiantan Hospital
Not applicable
450
Beijing
2025-12-30
Recruiting
Zhongshan Ophthalmic Center, Sun Yat-sen University
Early Phase 1
9
Beijing, Guangzhou
2025-12-29
Recruiting
Suzhou Immunofoco Biotechnology Co., Ltd
Early Phase 1
30
Beijing, Zhengzhou, Hangzhou
2025-12-29
Recruiting
Xuanwu Hospital, Beijing
Observational
2,600
Beijing
2025-12-29
Recruiting
Sinocelltech Ltd.
Phase 3
292
Beijing
2025-12-29
Recruiting
Sanofi
Phase 2
144
Beijing, Changsha, Hangzhou, Shanghai, Wuhan
2025-12-29
Recruiting
Alpha Biopharma (Jiangsu) Co., Ltd.
Observational
800
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Meizhou
2025-12-29
Recruiting
AstraZeneca
Phase 3
1,100
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-12-29
Recruiting
Jiangsu vcare pharmaceutical technology co., LTD
Phase 3
420
Beijing
2025-12-26
Recruiting
Chinese PLA General Hospital
Phase 1/2
40
Beijing
2025-12-26
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
70
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guiyang, Baoding, Harbin
2025-12-26
Recruiting
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
NCT07043894Solid Tumors, Hematological Tumor, Children, Adolescent
DrugIpilimumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
50
Beijing
2025-12-25
Active, closed
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
572
Beijing, Nanjing
2025-12-25
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
198
Beijing
2025-12-25
Not yet open
Peking Union Medical College Hospital
Phase 3
320
Beijing
2025-12-25
Recruiting
68Ga-BCMA PET/CT in Multiple Myeloma
NCT07319897Multiple Myeloma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Multiple Myeloma and Plasma Cell Neoplasm
Peking University First Hospital
Phase 2/3
300
Beijing, Shijiazhuang, Jilin City
2025-12-25
Recruiting
Xuanwu Hospital, Beijing
Phase 3
850
Beijing
2025-12-25
Not yet open
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
5,000
Beijing
2025-12-25
Recruiting
Peking Union Medical College Hospital
Phase 1/2
160
Beijing
2025-12-25
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
560
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Guangzhou, Meizhou, Shantou
2025-12-24
Recruiting
Peking Union Medical College Hospital
Phase 2
158
Beijing, Nanjing, Xuzhou
2025-12-24
Recruiting
Beijing Tide Pharmaceutical Co., Ltd
Phase 3
508
Beijing
2025-12-24
Recruiting
Shenzhen Majory Biotechnology Co., Ltd.
Phase 1/2
45
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou
2025-12-24
Active, closed
Xuanwu Hospital, Beijing
Phase 1
18
Beijing
2025-12-23
Recruiting
Eye & ENT Hospital of Fudan University
Phase 2
116
Harbin, Jinan, Beijing, Shanghai, Tianjin
2025-12-22
Recruiting
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
NCT07586813Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gastrointestinal Neoplasms, Pancreatic Cancer
DrugsTretinoin·All-trans retinoic acid·ATRA·Ipilimumab
Peking University People's Hospital
Phase 2
220
Beijing
2025-12-22
Recruiting
Eli Lilly and Company
Phase 3
800
Anyang, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang, Fuzhou Fujian
2025-12-22
Not yet open
Beijing Jishuitan Hospital
Not applicable
50
Beijing
2025-12-22
Recruiting
Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders
NCT07570212Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Peking University First Hospital
Not applicable
50
Beijing
2025-12-22
Recruiting
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
NCT07586826Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers, Ovarian Cancer
DrugsTretinoin·All-trans retinoic acid·ATRA·Ipilimumab
Peking University People's Hospital
Phase 2
220
Beijing
2025-12-22
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin
2025-12-19
Not yet open
China National Center for Cardiovascular Diseases
Phase 4
300
Beijing
2025-12-19
Active, closed
Capital Medical University
Not applicable
208
Fuyang, Suzhou, Beijing, Zhoukou, Shihezi
2025-12-18
Recruiting
TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
NCT07242417Solid Cancer, GPC3 Positive Hepatocellular Carcinoma
DrugsFludarabine·Cyclophosphamide
Beijing GoBroad Hospital
Early Phase 1
30
Beijing
2025-12-18
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
15
Beijing
2025-12-18
By invitation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
19
Beijing
2025-12-18
Recruiting
Capital Medical University
Phase 3
1,192
Anqing, Bozhou, Fuyang, Ma’anshan, Suzhou, Wuhu, Beijing, Fuzhou
2025-12-18
Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2
318
Beijing
2025-12-18
Recruiting
Sinotau Pharmaceutical Group
Phase 2
40
Beijing, Tianjin
2025-12-18
Recruiting
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 2
54
Beijing, Guangzhou
2025-12-18
Recruiting
Sanofi
Phase 3
85
Beijing, Wuhan
2025-12-18
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Shantou
2025-12-17
By invitation
Zhi-Jun Zhu
Early Phase 1
12
Beijing
2025-12-17
Recruiting
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
NCT07464132Tumor, Cardiovascular Diseases, Pulmonary Fibrosis, Rheumatic Immune Diseases Involving Large Blood Vessels
Drug68Ga-NI-FAPI
Peking Union Medical College Hospital
Phase 1/2
30
Beijing
2025-12-17
Recruiting
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
NCT07280832Unresectable Locally Advanced or Metastatic Melanoma, Unresectable Locally Advanced or Metastatic Urinary Tract Tumors
DrugJMT108
Shanghai JMT-Bio Inc.
Phase 1/2
500
Beijing
2025-12-17
Recruiting
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
NCT07311772Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis
Sun Yat-sen University
Phase 3
386
Beijing, Fuzhou, Guangzhou, Shantou, Zhuhai, Nanning, Wuzhou, Changsha
2025-12-16
Recruiting
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2
92
Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Changchun
2025-12-16
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
42
Beijing, Guangzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Dalian, Jinan
2025-12-16
Recruiting
Hutchmed
Phase 1/2
147
Beijing, Changsha, Guangzhou, Hefei, Shanghai, Shenyang, Zhengzhou
2025-12-16
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1
117
Bengbu, Beijing, Guangzhou, Changsha, Nanjing, Pingxiang, Shanghai, Taiyuan
2025-12-16
By invitation
Qian Jiang
Observational
100
Beijing
2025-12-16
Recruiting
Beijing Tiantan Hospital
Not applicable
750
Beijing
2025-12-15
Recruiting
Beijing Tiantan Hospital
Not applicable
750
Beijing
2025-12-15
Recruiting
AstraZeneca
Phase 2
320
Beijing, Changchun, Changsha, Guangzhou, Jiujiang, Kunming, Linyi, Nanchong
2025-12-15
Recruiting
Beijing Tiantan Hospital
Not applicable
750
Beijing
2025-12-15
Recruiting
Beijing Tiantan Hospital
Not applicable
750
Beijing
2025-12-15
Not yet open
Beijing Tsinghua Chang Gung Hospital
Observational
400
Beijing
2025-12-15
Recruiting
Beijing Tiantan Hospital
Not applicable
750
Beijing
2025-12-15
Recruiting
Peking Union Medical College Hospital
Not applicable
100
Beijing
2025-12-15
Recruiting
Eli Lilly and Company
Phase 3
1,035
Beijing, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang
2025-12-15
By invitation
Peking Union Medical College Hospital
Early Phase 1
8
Beijing
2025-12-15
Recruiting
Beijing Tiantan Hospital
Not applicable
832
Beijing
2025-12-15
Recruiting
Beijing Tiantan Hospital
Not applicable
750
Beijing
2025-12-15
Recruiting
Ming-an Yu
Not applicable
108
Beijing
2025-12-15
Recruiting
Beijing Tiantan Hospital
Not applicable
750
Beijing
2025-12-15
Not yet open
Beijing Anzhen Hospital
Not applicable
120
Beijing
2025-12-15
Recruiting
Hangzhou Qihan Biotech Co., Ltd.
Phase 1
18
Hefei, Wuhan, Beijing
2025-12-15
Active, closed
the Exploration of MTAP Deletion in Osteosarcoma by Immunohistochemistry
NCT07593573Osteosarcoma, MTAP Deletion, Immunohistochemistry
Peking University People's Hospital
Observational
100
Beijing
2025-12-15
Recruiting
Peking University First Hospital
Not applicable
50
Beijing
2025-12-15
Recruiting
Beijing Tiantan Hospital
Not applicable
86
Wuhu, Beijing
2025-12-12
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-12-12
Active, closed
Peking Union Medical College Hospital
Early Phase 1
12
Beijing
2025-12-12
Recruiting
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2
60
Beijing
2025-12-12
Active, closed
Cervical Cytology DNA Methylation for Endometrial Cancer Screening
NCT07874529Endometrial Cancer, DNA Methylation, Cytology, Cancer Screening
Lei Li
Observational
30,000
Beijing
2025-12-12
Recruiting
Pfizer
Phase 3
800
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-12-11
Recruiting
JHM BioPharma (Tonghua) Co. , Ltd.
Phase 3
207
Bengbu, Hefei, Beijing, Chongqing, Guangzhou, Nanning, Cangzhou, Shijiazhuang
2025-12-11
Active, closed
Biogen
Phase 4
12
Beijing
2025-12-11
Recruiting
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
NCT07326215Acute Respiratory Distress Syndrome, Acute Kidney Injury
Vantive Health LLC
Not applicable
99
Beijing, Guangzhou, Shenzhen, Harbin, Nanjing, Nanchang, Shanghai, Chengdu
2025-12-11
Recruiting
AI Facial Analysis Algorithm to Screening Coronary Artery Disease in High-Risk Community Population
NCT07277686Coronary Artery Disease (CAD), Artificial Intelligence Algorithms, Face, Screening
China National Center for Cardiovascular Diseases
Observational
1,392
Zhoukou, Beijing
2025-12-11
Recruiting
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
NCT07301164System Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myositis, Antiphospholipid Syndrome
Peking University Third Hospital
Early Phase 1
10
Beijing
2025-12-11
Recruiting
BeOne Medicines
Phase 1
86
Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Changsha, Nanjing, Shanghai
2025-12-11
Recruiting
BeOne Medicines
Phase 1
105
Beijing, Guangzhou, Harbin, Wuhan, Nanjing, Jinan, Weifang
2025-12-11
Recruiting
Xian-Janssen Pharmaceutical Ltd.
Observational
200
Beijing, Changzhou, Guangzhou, Hangzhou, Nanjing, Shenzhen, Shijiazhuang, Tianjin
2025-12-11
Recruiting
InSilico Medicine Hong Kong Limited
Phase 2
80
Beijing, Chongqing, Guangzhou, Huizhou, Nanning, Shijiazhuang, Luoyang, Xinxiang
2025-12-10
Recruiting
Danyang Huichuang Medical Equipment Co., Ltd.
Phase 3
320
Beijing, Shijiazhuang, Baotou, Suzhou, Xi'an, Shanghai, Taiyuan, Tianjin
2025-12-10
Not yet open
Songling Xuemaikang Capsules for Cerebral Small Vessel Disease
NCT07271732Hypertension, Cerebral Small Vessel Diseases
DrugSongling Xuemaikang
Dongzhimen Hospital, Beijing
Not applicable
90
Beijing
2025-12-10
Recruiting
China National Center for Cardiovascular Diseases
Not applicable
60
Beijing
2025-12-10
Not yet open
Abbisko Therapeutics Co, Ltd
Phase 1/2
110
Beijing, Zhengzhou, Wuhan, Shanghai, Chengde, Chengdu, Hangzhou
2025-12-10
Not yet open
Gait and Paraspinal sEMG in Degenerative Spinal Diseases
NCT07309926Adult Spinal Deformity, Degenerative Scoliosis, Sagittal Deformity, Sagittal Imbalance
Xuanwu Hospital, Beijing
Observational
120
Beijing
2025-12-10
Not yet open
The First Affiliated Hospital with Nanjing Medical University
Phase 2
156
Nanjing, Beijing
2025-12-10
Recruiting
The Impact of Image-Assisted Colonoscope on Patient Experience, Physician Workload, and Examination Quality
NCT07541924Colorectal Cancer Screening, Colonic Polyps/Colonoscopy/Colorectal Neoplasms, Difficult Colonoscopy, Colonoscopy-Related Discomfort
DONG WU
Not applicable
200
Beijing
2025-12-09
By invitation
Peking University First Hospital
Phase 2
30
Beijing
2025-12-09
Recruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 2
252
Beijing
2025-12-09
Recruiting
Tongji Hospital
Observational
40
Beijing, Guangzhou, Wuhan, Shanghai, Hangzhou
2025-12-09
Recruiting
Eli Lilly and Company
Phase 2
60
Beijing, Chengdu, Guangzhou, Luoyang, Shanghai, Xuzhou
2025-12-08
Recruiting
NWRD06 DNA Plasmid for HCC After Curative Resection.
NCT07324304Hepatocellular Carcinoma (HCC)
Newish Technology (Beijing) Co., Ltd.
Phase 2
30
Beijing, Harbin, Hangzhou
2025-12-08
Recruiting
Peking University Third Hospital
Observational
170
Beijing
2025-12-08
Not yet open
Xuanwu Hospital, Beijing
Not applicable
10
Beijing
2025-12-08
Recruiting
Beijing Tiantan Hospital
Phase 3
380
Beijing
2025-12-06
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
206
Beijing
2025-12-05
Active, closed
Zai Lab (Shanghai) Co., Ltd.
Phase 3
108
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou
2025-12-05
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 1
186
Beijing
2025-12-05
Recruiting
AstraZeneca
Phase 3
1,100
Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2025-12-04
Recruiting
Genfleet Therapeutics (Shanghai) Inc.
Phase 3
320
Beijing
2025-12-04
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
Beijing, Xiamen, Guangzhou, Harbin, Wuhan, Changsha, Nanjing, Nanchang
2025-12-04
Recruiting
Takeda
Phase 3
110
Beijing, Guangzhou, Changsha, Hangzhou, Shanghai
2025-12-04
Recruiting
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT07283835Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
DrugCretostimogene Grenadenorepvec
Lepu Biopharma Co., Ltd.
Phase 2
16
Beijing, Chongqing, Fuzhou, Wuhan, Changsha, Nanjing, Shenyang, Jinan
2025-12-04
Recruiting
BioNTech SE
Phase 2
105
Beijing, Changchun, Chengdu, Dalian, Guangzhou, Hangzhou, Jinan, Kunming
2025-12-04
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Hangzhou
2025-12-03
Recruiting
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
NCT07371663Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
Beijing Tide Pharmaceutical Co., Ltd
Phase 1/2
266
Beijing, Zhengzhou, Hangzhou
2025-12-03
Recruiting
Kind Pharmaceuticals LLC
Phase 3
240
Beijing
2025-12-03
Recruiting
Beijing Anzhen Hospital
Not applicable
296
Beijing
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
366
Beijing, Guangzhou, Shenzhen, Handan, Zhengzhou, Changsha, Jinan, Shanghai
2025-12-03
Recruiting
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 3
104
Beijing
2025-12-03
Recruiting
GlaxoSmithKline
Phase 3
450
Shijiazhuang, Shanghai, Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan
2025-12-03
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
662
Beijing
2025-12-02
Recruiting
Pfizer
Phase 3
450
Beijing, Shenzhen, Changsha, Nanchang, Hangzhou, Shanghai
2025-12-02
Recruiting
PTC-Guided Therapy for Peritoneal Mesothelioma
NCT07330271Peritoneal Mesothelioma
Beijing Tsinghua Chang Gung Hospital
Not applicable
347
Beijing
2025-12-02
Recruiting
Sanofi
Phase 2
37
Beijing, Shanghai, Shenzhen, Suzhou
2025-12-02
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
566
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-12-02
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
DrugSurovatamig
AstraZeneca
Phase 1
48
Beijing, Chengdu, Nanjing
2025-12-02
Recruiting
FAPI PET Imaging in Nonischemic Cardiomyopathy
NCT07878338Nonischemic Cardiomyopathy
Peking Union Medical College Hospital
Phase 2
400
Beijing
2025-12-02
Active, closed
Novartis Pharmaceuticals
Phase 2
234
Luoyang, Shenyang, Wenzhou, Beijing
2025-12-02
Recruiting
Bristol-Myers Squibb
Phase 3
650
Beijing, Haidian District, Guangzhou, Shenzhen, Changsha, Nanjing, Tianjin, Hangzhou
2025-12-02
Not yet open
For Patients With Myocardial Infarction and Multiple Vessel: Testing if Ultrasound (UFR) Can Guide All Needed Treatment in One Procedure, Avoiding a Return Hospital Visit for a Second Operation.
NCT07264881Microvascular Obstruction (MVO), Multivessel Coronary Artery Disease, ACS (Acute Coronary Syndrome), ST Elevation Myocardial Infarction (STEMI)
Beijing Anzhen Hospital
Observational
200
Beijing
2025-12-02
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
180
Beijing, Fuzhou, Guangzhou, Harbin, Anyang, Zhengzhou, Xuzhou, Shenyang
2025-12-02
Recruiting
Eye-Brain-Kidney in CKD
NCT07358572Chronic Kidney Diseases
Beijing Friendship Hospital
Observational
1,500
Beijing
2025-12-01
Recruiting
Guangzhou Gloria Biosciences Co., Ltd.
Phase 3
60
Beijing, Harbin
2025-12-01
Recruiting
MPR for Stroke Risk Assessment of ICAS
NCT07309718ICAS - Intracranial Atherosclerosis, Stroke Ischemic, Hemodynamic
Xuanwu Hospital, Beijing
Observational
400
Beijing
2025-12-01
Active, closed
Digital Angiography-Derived Fractional Flow Assessment for Intracranial Stenosis
NCT07309705Intracranial Atherosclerosis ICAS, Hemodynamic, Stroke
Xuanwu Hospital, Beijing
Observational
400
Beijing
2025-12-01
Recruiting
Dai, Guanghai
Phase 2
68
Beijing
2025-12-01
Recruiting
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Phase 3
360
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-12-01
Recruiting
Kira Pharmacenticals (US), LLC.
Phase 2
52
Beijing
2025-12-01
Recruiting
TCRx Therapeutics Co.Ltd
Phase 1
30
Beijing
2025-12-01
Recruiting
China National Center for Cardiovascular Diseases
Not applicable
200
Beijing
2025-12-01
Recruiting
Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Cervicogenic Headache
NCT07347730Myofascial Trigger Points, Cervicogenic Headache, Dorsal Root Ganglion
Beijing Tiantan Hospital
Not applicable
1,036
Beijing
2025-12-01
Not yet open
Zhijie Wang
Phase 2
28
Beijing
2025-12-01
Not yet open
Xuanwu Hospital, Beijing
Not applicable
25
Beijing
2025-12-01
Recruiting
Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Shoulder Osteoarthritis(OA)
NCT07347054Myofascial Trigger Points, Chronic Musculoskeletal Pain, Shoulder Osteoarthritis
Beijing Tiantan Hospital
Not applicable
1,036
Beijing
2025-12-01
Recruiting
Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Hip Osteoarthritis(OA)
NCT07347041Myofascial Trigger Points, Chronic Musculoskeletal Pain, Hip Osteoarthritis
Beijing Tiantan Hospital
Not applicable
1,036
Beijing
2025-12-01
Recruiting
Eli Lilly and Company
Phase 3
7,140
Beijing, Changchun, Changde, Changzhou, Chengdu, Chongqing, Dalian, Guangzhou
2025-12-01
Recruiting
Daihong Liu
Phase 4
324
Beijing
2025-12-01
Recruiting
Diagnostic Value of 68Ga-Pentixafor PET/CT in Adrenal Tumors With Aldosterone and Cortisol Cosecretion
NCT07605156Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion
Peking University First Hospital
Observational
130
Beijing
2025-12-01
Not yet open
A RCT of Moist Ag Dressing in Chronic Wound
NCT07235254Chronic Wound, Hard to Heal Wounds, Dressing, Wound he'a'Ling
Peking University Third Hospital
Not applicable
40
Beijing
2025-12-01
Recruiting
Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Migraine
NCT07347067Myofascial Trigger Points, Chronic Migraine Headache, Greater Occipital Nerve Block
Beijing Tiantan Hospital
Not applicable
1,036
Beijing
2025-12-01
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
84
Beijing, Fuzhou, Nanchang, Jinan, Shanghai, Hangzhou
2025-12-01
Not yet open
China National Center for Cardiovascular Diseases
Not applicable
170
Beijing
2025-12-01
Recruiting
Beijing Friendship Hospital
Phase 1/2
12
Beijing
2025-12-01
Not yet open
A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
NCT07169175Amyotrophic Lateral Sclerosis (ALS)
DrugSNUG01
SineuGene Therapeutics Co., Ltd.
Phase 1/2
21
Beijing, Fuzhou, Hangzhou
2025-12-01
Recruiting
Central China Fuwai Hospital of Zhengzhou University
Not applicable
738
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Qingdao
2025-12-01
Recruiting
Beijing 302 Hospital
Phase 1
5
Beijing
2025-12-01
Recruiting
Beijing University of Chinese Medicine
Phase 4
100
Beijing
2025-12-01
Active, closed
Peking University Third Hospital
Not applicable
50
Beijing
2025-12-01
Active, closed
UCB Biopharma SRL
Phase 4
40
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Jinan, Shanghai, Shenzhen
2025-12-01
Recruiting
Cascade Pharmaceuticals, Inc
Phase 3
135
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhanjiang, Nanning
2025-12-01
Active, closed
AI Chatbots for Anxiety Mental Health Literacy
NCT07316374Anxiety Literacy, Anxiety Disorders, Mental Health Literacy
Peking University
Not applicable
200
Beijing
2025-12-01
Not yet open
Shanghai Changzheng Hospital
Observational
1,100
Beijing, Guangzhou, Nanjing, Suzhou, Shanghai, Chengdu, Ningbo
2025-12
Recruiting
Neowise Biotechnology
Phase 1
24
Beijing
2025-12
Recruiting
Keymed Biosciences Co.Ltd
Phase 2
246
Beijing
2025-12
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
40
Beijing
2025-12
Recruiting
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
NCT07441291B ALL, Allogenetic Hematopoietic Stem Cell Transplantation, MRD-positive
DrugCar-T
Peking University People's Hospital
Phase 3
70
Beijing
2025-11-30
Not yet open
Peking University Third Hospital
Not applicable
147
Beijing
2025-11-30
Not yet open
Xuanwu Hospital, Beijing
Not applicable
160
Beijing
2025-11-30
Recruiting
Beijing Tiantan Hospital
Observational
10,000
Beijing
2025-11-30
Recruiting
Henan Genuine Biotech Co., Ltd.
Phase 2
24
Beijing
2025-11-29
Recruiting
AstraZeneca
Not applicable
3,000
Anqing, Beijing, Changsha, Chaohu, Chengdu, Chifeng, Chongqing, Dalian
2025-11-28
Active, closed
Dr. Willmar Schwabe GmbH & Co. KG
Phase 4
400
Anyang, Baotou, Beijing, Benxi, Chenzhou, Chifeng, Dalian, Harbin
2025-11-28
Recruiting
Capital Medical University
Phase 3
384
Beijing
2025-11-28
Recruiting
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
150
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Nanning, Shijiazhuang
2025-11-27
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Jingzhou, Changsha
2025-11-27
Recruiting
A Prediction Model in Pregnant Women With Aplastic Anemia
NCT07101770Aplastic Anemia, Pregnancy, Prediction Model
Peking University People's Hospital
Observational
300
Beijing
2025-11-27
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
36
Beijing
2025-11-27
Recruiting
Henan Genuine Biotech Co., Ltd.
Phase 1/2
110
Beijing, Changsha, Jinan, Xiamen, Zhengzhou
2025-11-27
Recruiting
Novartis Pharmaceuticals
Phase 3
31
Hangzhou, Beijing
2025-11-27
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 2
78
Beijing, Guangzhou, Hangzhou, Nanchang
2025-11-26
Recruiting
Establishment of a Multimodal Standard Database for Inflammation-related Ophthalmopathy
NCT07628946Ocular Surface Disease, Inflammatory Disease, Retinal Disease, Choroid Diseases
Dan Chen
Observational
3,000
Beijing
2025-11-26
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO Resistant Squamous and Nonsquamous NSCLC
Takeda
Phase 3
1,200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Xinxiang
2025-11-26
Recruiting
Beijing Tongren Hospital
Phase 4
88
Beijing
2025-11-25
Recruiting
AbbVie
Phase 2
180
Beijing, Zhengzhou, Wuhan, Nanchang, Shanghai, Chengdu
2025-11-25
Active, closed
VivaVision Biotech, Inc
Phase 3
154
Chongqing, Beijing
2025-11-25
Active, closed
Effect of Perception-based Interventions on Public Acceptance of Using Large Language Models in Medicine
NCT07304908Large Language Models, Acceptability of Health Care, Perception, Self
Peking University
Not applicable
3,000
Beijing
2025-11-25
Recruiting
Shanghai Henlius Biotech
Phase 1
246
Beijing, Bengbu, Changchun, Changsha, Chengdu, Dongguan, Fuzhou, Ganzhou
2025-11-25
Not yet open
Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome
NCT07240376Non-Allergic Rhinitis With Eosinophilia Syndrome
DrugStapokibart
Huazhong University of Science and Technology
Not applicable
90
Guangzhou, Wuhan, Xiangyang, Nanchang, Chengdu, Beijing, Shanghai
2025-11-25
Recruiting
Peking University Cancer Hospital & Institute
Phase 2
26
Beijing
2025-11-25
Recruiting
A Phase Ia Clinical Trial of HW241045
NCT07448194Healthy Volunteers, IPF
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase 1
56
Beijing
2025-11-24
Not yet open
Zhang Jianguo
Not applicable
86
Beijing, Wuhan, Nanjing, Dalian, Jinan, Shanghai, Tianjin, Hangzhou
2025-11-24
Recruiting
Hoffmann-La Roche
Phase 3
900
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing
2025-11-24
Recruiting
Peking University
Not applicable
184
Beijing, Fuzhou
2025-11-22
Recruiting
Peking University Third Hospital
Not applicable
45
Beijing
2025-11-22
Recruiting
Kunming Pharmaceuticals, Inc.
Phase 2
300
Beijing, Shenzhen, Cangzhou, Hengshui, Daqing, Anyang, Nanyang, Xuzhou
2025-11-22
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
50
Beijing
2025-11-21
Active, closed
Qilu Pharmaceutical Co., Ltd.
Phase 3
146
Bengbu, Beijing, Chongqing, Lanzhou, Haikou, Zhengzhou, Changsha, Nanjing
2025-11-21
Recruiting
GlaxoSmithKline
Phase 3
75
Leshan, Beijing, Changsha, Chengdu, Chongqing, Dongguan, Ganzhou, Guangzhou
2025-11-21
Recruiting
Huashan Hospital
Phase 4
426
Beijing, Liupanshui, Nayong, Shanghai, Hangzhou
2025-11-21
Recruiting
TJ Biopharma Co., Ltd.
Phase 3
30
Beijing, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Nanchang, Shenyang
2025-11-21
Recruiting
Beijing Tongren Hospital
Phase 2
50
Beijing
2025-11-20
Not yet open
The Affiliated Hospital of Xuzhou Medical University
Phase 4
1,160
Fuyang, Huai'an, Lianyungang, Nanjing, Suqian, Xuzhou, Beijing, Shanghai
2025-11-20
Recruiting
Pfizer
Phase 2
165
Fuzhou, Guangzhou, Shanghai, Beijing
2025-11-20
Recruiting
Nanjing Jingao biomidical technology Co. Ltd.
Phase 1/2
20
Beijing
2025-11-20
Recruiting
The Feasibility Study of Polymer Artificial Heart Valve for the Treatment the Mitral Valve Disease.
NCT07243184Severe Mitral Valve Regurgitation, Severe Mitral Valve Stenosis
Shanghai HeartEpoch Medical Technology Co., Ltd
Not applicable
10
Beijing
2025-11-19
Recruiting
Beijing Tiantan Hospital
Not applicable
770
Beijing, Xiamen, Jiangmen, Shantou, Shenzhen, Liuzhou, Nanning, Wuzhou
2025-11-19
Active, closed
MedtronicNeuro
Not applicable
61
Beijing, Guangzhou, Shanghai, Chengdu
2025-11-19
Active, closed
Bayer
Phase 2
60
Beijing, Guangzhou, Wuhan, Hangzhou
2025-11-19
Recruiting
Summit Therapeutics
Phase 3
900
Beijing, Fuzhou, Guangzhou, Foshan, Shenzhen, Zhuhai, Haikou, Shijiazhuang
2025-11-18
Recruiting
Hangzhou Sciwind Biosciences Co., Ltd.
Phase 1/2
126
Beijing
2025-11-18
Recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
96
Beijing
2025-11-18
By invitation
Peking Union Medical College Hospital
Early Phase 1
30
Beijing
2025-11-17
Recruiting
Jiangsu Nutai Biologics Co., Ltd
Phase 1
54
Beijing
2025-11-17
Recruiting
Sanofi
Observational
1,000
Beijing, Shenzhen, Changsha, Xi’an, Chengdu, Hangzhou, Ningbo, Chongqing
2025-11-17
Recruiting
Gan & Lee Pharmaceuticals.
Phase 1
60
Beijing
2025-11-17
Recruiting
AstraZeneca
Observational
200
Beijing, Cangzhou, Dongguan, Fuzhou, Guangzhou, Huzhou, Jinan, Nanjing
2025-11-17
Recruiting
Peking University
Not applicable
500
Beijing
2025-11-16
Recruiting
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
NCT07209813Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
DrugGKL-006
Beijing Gene Key Life Technology Co., Ltd
Phase 2
48
Beijing, Zhengzhou, Changsha, Nanjing, Nanchang, Hangzhou
2025-11-14
Recruiting
Sinotau Pharmaceutical Group
Phase 3
395
Beijing, Foshan, Tianjin
2025-11-14
Recruiting
UCB Biopharma SRL
Phase 3
320
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Shenzhen
2025-11-14
Recruiting
Degron Therapeutics Co.
Phase 1
100
Beijing, Guangzhou
2025-11-13
Recruiting
Registry Study of Cerebral Small Vessel Disease
NCT07342075Cerebral Small Vessel Diseases, Cognitive Impairment, Diffusion Tensor Imaging
Dongzhimen Hospital, Beijing
Observational
50
Beijing
2025-11-13
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing, Zhengzhou, Shenyang, Taiyuan
2025-11-12
Recruiting
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
312
Beijing, Zhengzhou
2025-11-12
Recruiting
Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL
NCT07175662High-grade Squamous Intraepithelial Lesion (HSIL)
Newish Biotech (Wuxi) Co., Ltd.
Phase 2
150
Beijing, Taiyuan
2025-11-11
Recruiting
Peking University Third Hospital
Not applicable
50
Beijing
2025-11-11
Recruiting
AstraZeneca
Phase 3
420
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Haikou
2025-11-11
Recruiting
Real-world Study of Aflibercept 8 mg in nAMD
NCT07640997Neovascular Age-Related Macular Degeneration (nAMD)
DrugAflibercept
Peking University People's Hospital
Observational
300
Beijing, Fuzhou, Shenzhen, Zunyi, Harbin, Nanyang, Wuhan, Hohhot
2025-11-11
Not yet open
Chengdu Kangnuoxing Biopharma,Inc.
Phase 3
200
Beijing
2025-11-11
Recruiting
Beijing Anzhen Hospital
Phase 4
976
Beijing
2025-11-11
Recruiting
Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
NCT07232654LOCALLY ADVANCED CERVICAL CANCERS
DrugsLenvatinib·Cisplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2025-11-11
Recruiting
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase 3
300
Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Meizhou, Shaoguan, Shenzhen
2025-11-10
Recruiting
BeOne Medicines
Phase 1
63
Beijing, Chongqing, Xiamen, Harbin, Zhengzhou, Shanghai, Chengdu, Hangzhou
2025-11-10
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
232
Beijing, Nanjing, Shanghai, Tianjin, Wuhan
2025-11-07
Recruiting
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
500
Beijing
2025-11-07
Recruiting
Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Phase 1/2
660
Beijing
2025-11-07
Recruiting
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
NCT06902740Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque
Peking Union Medical College Hospital
Phase 4
300
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2025-11-07
Recruiting
SPH Qingdao Growful Pharmacetical Co.,Ltd
Phase 4
2,708
Haozhou, Beijing, Chongqing, Lanzhou, Guangzhou, Shantou, Zhuhai, Guilin
2025-11-06
Recruiting
VivaVision Biotech, Inc
Phase 1
60
Beijing
2025-11-06
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Beijing, Chongqing, Fuzhou, Jiangmen, Anyang, Luoyang, Jingzhou, Wuhan
2025-11-05
Active, closed
Suzhou HepaThera Biotech Co., Ltd.
Phase 2
60
Beijing, Fuzhou, Guangzhou, Qingyuan, Nanning, Zhengzhou, Nanjing, Zhenjiang
2025-11-05
Recruiting
Beijing Friendship Hospital
Phase 2
32
Beijing
2025-11-04
Recruiting
Eli Lilly and Company
Phase 2
222
Beijing, Chengdu, Chongqing, Hangzhou, Linhai, Ningbo, Shenzhen
2025-11-03
Recruiting
Guangdong Association of Clinical Trials
Phase 2
48
Guangzhou, Beijing, Foshan, Nanchang, Nanning, Shijiazhuang
2025-11-03
Recruiting
Beijing Tiantan Hospital
Not applicable
4,000
Beijing
2025-11-03
Recruiting
Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques
NCT06855537Coronary Arterial Disease (CAD), Vulnerable Coronary Plaques, Thin-cap fIbroatheroma, Acute Coronary Syndromes (ACS)
Beijing Anzhen Hospital
Phase 4
2,190
Beijing
2025-11-03
Recruiting
Peking Union Medical College Hospital
Not applicable
110
Beijing
2025-11-01
Recruiting
Peking University First Hospital
Phase 1
12
Beijing
2025-11-01
By invitation
Ming Yang
Observational
380
Beijing
2025-11-01
Recruiting
Takeda
Observational
200
Hefei, Beijing, Fuzhou, Hangzhou, Shantou, Shenzhen, Shijiazhuang, Harbin
2025-11-01
Recruiting
CONNEctome-guided Navigation for Eloquent-area Tumor Surgery Trial
NCT07657403Brain Neoplasms, Eloquent Area Brain Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
200
Beijing
2025-11-01
Recruiting
Beijing Tsinghua Chang Gung Hospital
Not applicable
132
Beijing
2025-11-01
Recruiting
CAIX PET/ CT Guided Radiation Therapy in CcRCC.
NCT07540260Radiation Therapy, Metastatic Renal Cancer, Recurrent Renal Cell Cancer
Peking University First Hospital
Not applicable
70
Beijing
2025-11-01
Recruiting
Peking University Third Hospital
Not applicable
30
Beijing
2025-11-01
Recruiting
TAIC FOLFOX for Locally Advanced G/GEJA
NCT07655024Gastric Cancer (Diagnosis), Gastroesophageal Junction Adenocarcinoma
DrugFolfox
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Phase 2
31
Beijing
2025-11-01
By invitation
Peking University
Phase 2
48
Beijing
2025-11-01
Not yet open
Peking University First Hospital
Not applicable
1,508
Beijing, Tianjin
2025-11
Not yet open
Jing Liu
Phase 4
104
Beijing
2025-11
Not yet open
Fengliao Changweikang for Diarrhea-predominant Irritable Bowel Syndrome: N-of-1 Trial
NCT07061184Irritable Bowel Syndrome - Diarrhoea, Traditional Chinese Medicine (TCM), N of 1 Study Design, Efficacy and Safety
Peking Union Medical College Hospital
Phase 4
50
Beijing
2025-11
Not yet open
Beijing Suncadia Pharmaceuticals Co., Ltd
Phase 1
48
Beijing
2025-11
Not yet open
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
228
Beijing, Chongqing, Lanzhou, Guangzhou, Guiyang, Haikou, Harbin, Zhengzhou
2025-11
Recruiting
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase 3
406
Beijing, Xiamen, Guangzhou, Zunyi, Luoyang, Zhengzhou, Wuhan, Xiangtan
2025-10-31
Recruiting
Jiangsu vcare pharmaceutical technology co., LTD
Phase 2
120
Beijing
2025-10-31
Recruiting
Eli Lilly and Company
Phase 3
1,205
Beijing, Chengdu, Guangzhou, Harbin, Luoyang Shi, Nanjing, Shanghai, Tianjin
2025-10-31
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
20
Beijing, Chongqing
2025-10-31
Recruiting
AstraZeneca
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-10-31
Recruiting
Evaluation of the Safety and Effectiveness of CHORDS® Cerebral Protection System During TAVR: DUET Trial
NCT07648693Transcatheter Aortic Valve Replacement (TAVR), Cerebral Vascular Accident (CVA)/Stroke
Resonova (Shanghai) Medtech Limited
Not applicable
240
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanchang, Qingdao
2025-10-31
Recruiting
AstraZeneca
Phase 3
100
Beijing, Changsha, Guangzhou, Linyi, Shandong, Wuhan, Zhengzhou
2025-10-30
Not yet open
Peking University People's Hospital
Phase 1/2
138
Beijing
2025-10-30
Not yet open
Xuanwu Hospital, Beijing
Early Phase 1
40
Beijing
2025-10-30
Recruiting
Dynamic Airway Resistance & ML: Guide Sputum Suction in Ventilated Patients
NCT07375667Mechanical Ventilation Pressure High, Ventilator-Associated Pneumonia (VAP), Respiratory Depression Neonatal
Affiliated Hospital of Nantong University
Not applicable
258
Bengbu, Beijing, Hangzhou
2025-10-30
Recruiting
Pfizer
Phase 2
200
Beijing, Guangzhou, Shijiazhuang, Shanghai, Tianjin, Hangzhou
2025-10-30
Recruiting
Shanghai Zhimeng Biopharma, Inc.
Phase 2/3
240
Beijing
2025-10-30
Recruiting
Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.
NCT07569653Cytomegalovirus Infections, Cytomegalovirus Disease, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
WeiShi
Phase 4
120
Beijing, Shijiazhuang, Zhengzhou, Jingzhou, Wuhan, Hohhot, Nanchang, Wenzhou
2025-10-30
Recruiting
GlaxoSmithKline
Phase 2
363
Beijing, Chongqing, Dongguan, Guangzhou, Guilin, Hangzhou, Huizhou, Jiangmen
2025-10-30
Recruiting
BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation
NCT07246031Graft -Versus-host-disease, aGVHD, Haploidentical Stem Cell Transplantation, cGVHD
BioPhoenix Co., Ltd.
Phase 2
50
Beijing, Wuhan
2025-10-29
Active, closed
GlaxoSmithKline
Phase 3
750
Beijing, Xiangtan, Nanjing, Chengdu, Chongqing, Guangzhou, Jiujiang, Kunming
2025-10-29
Recruiting
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
270
Beijing
2025-10-29
Recruiting
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1
12
Beijing, Changchun, Guangzhou, Hangzhou, Suzhou, Wenzhou, Wuhan
2025-10-29
Recruiting
A Study of Ivonescimab in First-Line ES-SCLC
NCT07245446Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DrugsLigufalimab·Cadonilimab·Ivonescimab·Etoposide
Akeso
Phase 2
180
Beijing, Xi'an, Shanghai
2025-10-29
Active, closed
Kylonova (Xiamen) Biopharma co., LTD.
Phase 2
204
Beijing, Baotou, Changde, Chongqing, Dali, Daqing, Guangzhou, Harbin
2025-10-29
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
108
Beijing
2025-10-28
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
120
Beijing
2025-10-28
Recruiting
Novartis Pharmaceuticals
Phase 2
165
Beijing, Xi'an
2025-10-28
Recruiting
Shenzhen Kexing Pharmaceutical Co., Ltd.
Phase 1
36
Beijing
2025-10-28
Recruiting
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
NCT07082842Idiopathic Pulmonary Fibrosis (IPF)
DrugsHEC585·Pirfenidone
Sunshine Lake Pharma Co., Ltd.
Phase 3
472
Beijing
2025-10-27
Active, closed
AstraZeneca
Observational
251
Beijing, Chongqing, Quanzhou, Lanzhou, Shenzhen, Zhanjiang, Nanning, Guiyang
2025-10-27
Recruiting
A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
NCT07641634Healthy Volunteers, Systemic Sclerosis (SSc), Scleroderma, Systemic, Scleroderma
Prolium Bioscience, Inc
Phase 1/2
44
Beijing, Guangzhou, Henan, Nanchang, Nanjing, Pingxiang
2025-10-27
Recruiting
A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis
NCT07499700Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS)
DrugBAT4406F
Bio-Thera Solutions
Phase 2/3
192
Beijing
2025-10-26
Recruiting
Xuanwu Hospital, Beijing
Not applicable
750
Guangdong, Baotou, Beijing, Bozhou, Changsha, Changzhi, Changzhou, Chifeng
2025-10-24
Recruiting
Hoffmann-La Roche
Phase 3
600
Hefei, Nanchang, Hangzhou, Beijing, Bengbu, Changsha, Chengdu, Guangzhou
2025-10-24
Recruiting
Zhejiang University
Not applicable
410
Beijing, Jinjiang, Hangzhou, Lishui, Taizhou
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-10-24
Active, closed
Boston Scientific Corporation
Observational
501
Beijing
2025-10-23
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Luoyang, Zhengzhou
2025-10-23
Recruiting
Eli Lilly and Company
Phase 2
531
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai
2025-10-22
Recruiting
68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
NCT07508852SCLC, SCLC, Extensive Stage, SCLC, Limited Stage, Small Cell Lung Cancer
Peking University First Hospital
Phase 1/2
30
Beijing
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
1,630
Beijing, Changchun, Changde, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan
2025-10-22
Recruiting
Peking Union Medical College Hospital
Phase 4
210
Beijing
2025-10-22
Recruiting
Jemincare
Phase 1
102
Beijing
2025-10-22
Recruiting
Beijing GoBroad Hospital
Observational
20
Beijing
2025-10-22
Recruiting
Beijing Chao Yang Hospital
Phase 4
966
Beijing
2025-10-21
Recruiting
Beijing Tide Pharmaceutical Co., Ltd
Phase 1
90
Beijing
2025-10-21
Recruiting
Complex Arrhythmia Registry
NCT07024927Atrial Fibrillation (AF), Ventricular Tachycardia (VT)
Beijing Anzhen Hospital
Observational
4,000
Beijing
2025-10-21
Recruiting
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
126
Beijing, Guangzhou, Zhengzhou, Wuhan
2025-10-21
Recruiting
KD Treatment for Super-refractory Status Epilepticus
NCT07496749Super-refractory Status Epilepticus
Xuanwu Hospital, Beijing
Not applicable
84
Hefei, Beijing, Fuzhou, Nanning, Guiyang, Haikou, Shijiazhuang, Harbin
2025-10-20
Recruiting
Haplo-Cord HSCT for AML/MDS
NCT07588360MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia)
Fujian Medical University Union Hospital
Not applicable
82
Fuzhou, Guangzhou, Chengdu, Beijing
2025-10-20
Recruiting
Beijing Tiantan Hospital
Not applicable
384
Beijing
2025-10-20
Recruiting
GlaxoSmithKline
Phase 3
1,196
Shapingba, Nanning, Chengdu, Suining, Beijing, Changchun, Changsha, Chongqing
2025-10-20
Recruiting
Chinese PLA General Hospital
Observational
30
Beijing
2025-10-20
Active, closed
BeiGene
Phase 4
16
Beijing, Guangzhou, Baoding, Yichang, Changsha, Hangzhou
2025-10-17
Recruiting
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2025-10-16
Recruiting
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
NCT07209761Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis
DrugsPretomanid·Bedaquiline·Linezolid·Moxifloxacin
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
532
Beijing, Fuzhou, Shenzhen, Wuhan, Nanjing, Jinan, Shanghai, Chengdu
2025-10-16
Recruiting
Tao Liu
Not applicable
143
Beijing, Tianjin
2025-10-15
Recruiting
Beijing Tiantan Hospital
Not applicable
216
Beijing
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Huzhou
2025-10-15
Recruiting
Bristol-Myers Squibb
Phase 1
32
Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin
2025-10-15
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Beijing
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
4,500
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Guiyang
2025-10-15
Active, closed
Beijing Anzhen Hospital
Observational
400
Beijing
2025-10-14
Recruiting
Ventricular Tachycardia：A Registry Study
NCT07149701Ventricular Tachycardia (VT), Structural Heart Disease
Beijing Anzhen Hospital
Observational
1,000
Beijing
2025-10-14
Recruiting
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
NCT07787182Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
DrugLY4405094
Eli Lilly and Company
Phase 1
68
Beijing, Minhang District, Shanghai
2025-10-14
By invitation
Changchun BCHT Biotechnology Co.
Phase 1
144
Beijing
2025-10-13
Recruiting
Takeda
Phase 3
20
Beijing, Guangzhou, Jihan, Shanghai, Suzhou, Tianjin, Wuhan
2025-10-13
Recruiting
Xinxin Zhang
Early Phase 1
5
Beijing
2025-10-13
Recruiting
Changhai Hospital
Not applicable
1,250
Baotou, Beijing, Hangzhou, Hunan, Lanzhou, Shandong, Shanghai, Yunnan
2025-10-13
Recruiting
Xuanwu Hospital, Beijing
Not applicable
364
Fuzhou, Zhangzhou, Beijing
2025-10-12
Recruiting
Hinova Pharmaceuticals Inc.
Phase 2
80
Beijing, Chengdu
2025-10-11
Recruiting
Prospective Study Protocol for Multiparametric PCCT Assessment of Early Ventricular Outcomes After CABG
NCT07883499Coronary Artery Bypass Grafting (CABG) Surgery, Coronary Artery Disease
Xin Lou
Observational
150
Beijing
2025-10-10
Not yet open
Beijing Tiantan Hospital
Phase 2
1,950
Beijing
2025-10-10
Recruiting
The Effectiveness of Guided Written Exposure Therapy for Complex PTSD in Adolescents
NCT07325734CPTSD, Compelx Post-traumatic Stress Disorder
Peking University
Not applicable
130
Fuyang, Beijing, Ulanhot, Ürümqi
2025-10-10
Not yet open
A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.
NCT07190716Single Ascending Dose, Healthy Subjects
DrugGR2301
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 1
36
Beijing
2025-10-10
Recruiting
Beijing Tongren Hospital
Phase 1
10
Beijing
2025-10-09
Recruiting
Beijing Tiantan Hospital
Phase 3
364
Beijing
2025-10-09
Recruiting
Bristol-Myers Squibb
Phase 3
424
Beijing, Guangzhou, Baoding, Shijiazhuang, Changsha, Nanjing, Xi'an, Chengdu
2025-10-08
Active, closed
Merck Sharp & Dohme LLC
Phase 2
185
Beijing, Xiamen, Guangzhou, Xinxiang, Pingxiang, Linfen, Ürümqi, Linhai
2025-10-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Hefei, Beijing, Fujian, Fuzhou, Guangzhou, Nanning, Jiamusi, Zhengzhou
2025-10-08
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou
2025-10-03
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Beijing, Guangzhou, Luoyang, Xuzhou, Nanchang, Wenzhou, Fuzhou, Jining
2025-10-03
Recruiting
Pfizer
Phase 2/3
982
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Baoding, Langfang
2025-10-03
Recruiting
Light and Anesthesia
NCT07517484Light, Anesthesia, Sedation
Peking University People's Hospital
Not applicable
66
Beijing
2025-10-03
Active, closed
Peking University
Not applicable
980
Beijing
2025-10-02
Recruiting
Novo Nordisk A/S
Phase 3
1,280
Hefei, Beijing, Changchun, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Harbin
2025-10-02
Recruiting
Time to Ambulation After ProGlide Closure
NCT07179536Femoral Access Site Closure, Ambulation, Vascular Access Complication, Vascular Access Site Management
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
300
Beijing
2025-10-01
Recruiting
Capital Medical University
Not applicable
300
Hunan, Guangxi, Beijing, Jilin City, Henan
2025-10-01
Recruiting
Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis
NCT07488728EBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis, Letermovir
DrugLetermovir
Beijing Children's Hospital
Not applicable
80
Beijing
2025-10-01
Not yet open
zhoujing
Phase 2
35
Beijing
2025-10-01
Not yet open
Beijing 302 Hospital
Phase 2
155
Beijing
2025-10-01
Active, closed
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
20,000
Beijing
2025-10-01
Active, closed
Peking Union Medical College Hospital
Observational
60
Beijing
2025-10-01
Active, closed
TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.
NCT07176754Cardiac Arrest (CA), Post Cardiac Arrest Syndrome
DrugInfliximab
Peking University Third Hospital
Not applicable
208
Beijing
2025-10-01
Not yet open
High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC
NCT07182708NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation, Resectable Lung Non-Small Cell Carcinoma
DrugsFirmonertinib Mesilate·Bevacizumab
Peking University Cancer Hospital & Institute
Phase 2
62
Beijing
2025-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
896
Beijing, Changzhou, Cheng Du Shi, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou
2025-10-01
Recruiting
Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer
NCT07200141Locally Advanced Rectal Adenocarcinoma
Peking Union Medical College Hospital
Phase 2
156
Beijing
2025-10-01
Active, closed
Obesity Prevention in School-aged Children
NCT07203300Childhood Obesity Prevention
Peking University
Not applicable
1,400
Beijing
2025-10-01
Recruiting
Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Knee Osteoarthritis(OA)
NCT07347028Myofascial Trigger Points, Migraine, Cervicogenic Headache, Chronic Musculoskeletal Pain
Beijing Tiantan Hospital
Not applicable
238
Beijing
2025-10-01
Not yet open
Shanghai IxCell Biotechnology Co., LTD
Phase 2
86
Beijing
2025-10-01
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
300
Beijing
2025-10-01
Not yet open
Yanbing Li
Observational
594
Hangzhou, Baoding, Beijing, Shanghai, Xi'an
2025-10-01
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
65
Beijing
2025-10-01
Recruiting
Capital Medical University
Observational
100
Beijing
2025-10-01
Recruiting
Urokinase for Thrombolysis in Acute Ischemic Stroke
NCT07047326Acute Ischemic Stroke
Capital Medical University
Not applicable
24
Beijing, Handan
2025-10-01
Recruiting
Huashan Hospital
Phase 2/3
215
Beijing, Chengdu, Fuzhou, Guangzhou, Jinan, Nanchang, Nanjing, Shanghai
2025-10-01
Not yet open
GeneCradle Inc
Phase 1/2
15
Beijing
2025-10
Recruiting
A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases
NCT07167537Systemic Sclerosis (SSc), Primary Sjogren's Syndrome
Beijing GoBroad Hospital
Phase 1
44
Beijing
2025-10
Recruiting
Beijing Tiantan Hospital
Not applicable
1,116
Beijing
2025-09-30
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Changsha, Nanjing, Nantong
2025-09-30
Not yet open
Beijing Friendship Hospital
Not applicable
256
Beijing, Changsha, Chengdu, Guangzhou, Jinan, Kunming, Nanjing, Shanghai
2025-09-30
Recruiting
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
NCT07145151Metabolic Dysfunction-associated Steatohepatitis (MASH)
DrugUBT251
The United Bio-Technology (Hengqin) Co., Ltd.
Phase 2
156
Beijing
2025-09-30
Recruiting
Beijing Tiantan Hospital
Not applicable
440
Beijing
2025-09-30
Not yet open
Chinese PLA General Hospital
Early Phase 1
12
Beijing
2025-09-30
Recruiting
AstraZeneca
Phase 1/2
52
Beijing, Chengdu, Guangzhou, Nanjing
2025-09-30
Recruiting
Eli Lilly and Company
Phase 3
1,000
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Lanzhou, Nanjing
2025-09-30
Not yet open
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3
204
Beijing
2025-09-30
Not yet open
Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC
NCT07200154Limited-stage Small-cell Lung Cancer, Concurrent Chemoradiation Therapy
Peking University Cancer Hospital & Institute
Phase 2
30
Beijing
2025-09-30
Recruiting
Beijing Tiantan Hospital
Not applicable
400
Beijing
2025-09-30
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Baotou, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Dongguan
2025-09-30
Recruiting
Daiichi Sankyo
Phase 3
710
Beijing, Changchun, Chengdu, Hangzhou, Jinan, Linyi, Nanchang, Nanning
2025-09-30
Recruiting
Peking University Third Hospital
Observational
480
Beijing
2025-09-30
Recruiting
Daihong Liu
Phase 2
25
Beijing
2025-09-29
Recruiting
Pfizer
Phase 3
680
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Wuhan
2025-09-29
Recruiting
Hoffmann-La Roche
Observational
300
Langfang, Tianjin, Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan
2025-09-29
Recruiting
Pfizer
Phase 3
1,000
Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Wuhan, Changsha, Huai'an
2025-09-28
Active, closed
Shanghai Henlius Biotech
Phase 1
174
Hefei, Wuhu, Beijing, Hunan, Fuzhou, Xiamen, Lanzhou, Cangzhou
2025-09-26
Recruiting
Merck Sharp & Dohme LLC
Phase 2
315
Bengbu, Beijing, Guangzhou, Luoyang, Pingxiang, Changchun, Ürümqi, Kunming
2025-09-26
Recruiting
Daiichi Sankyo
Phase 2/3
630
Beijing, Chengdu, Guangzhou
2025-09-26
Recruiting
Sanofi
Phase 3
124
Beijing, Chengdu, Hangzhou, Jiazhuang, Taiyuan, Wuhan, Yantai
2025-09-26
Active, closed
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
NCT07107256Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
DrugTQC2731
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
246
Fuyang, Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-09-25
Recruiting
MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer
NCT07584161Cervical Cancer, Endometrial Cancer
Xiaorong Hou
Not applicable
228
Beijing
2025-09-25
Not yet open
Advancing Assessment for Disorders of Consciousness
NCT07180589Disorders of Consciousness
Xuanwu Hospital, Beijing
Observational
200
Beijing
2025-09-25
Recruiting
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
NCT07188610CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou
2025-09-25
Not yet open
Peking University Cancer Hospital & Institute
Phase 3
116
Beijing
2025-09-25
Recruiting
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 1/2
198
Beijing
2025-09-24
Recruiting
Capital Medical University
Not applicable
240
Ma’anshan, Beijing, Zhangzhou, Heyuan, Qinzhou, Baoding, Harbin, Jiamusi
2025-09-24
Recruiting
Peking Union Medical College Hospital
Observational
343
Beijing
2025-09-24
Recruiting
Zuojun Xu
Observational
600
Beijing
2025-09-23
Recruiting
Gan & Lee Pharmaceuticals.
Phase 3
420
Beijing
2025-09-23
Recruiting
Shanghai Chest Hospital
Phase 2
96
Hefei, Beijing, Zhengzhou, Shanghai
2025-09-22
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 2
86
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2025-09-22
Not yet open
BrosMed Medical Co., Ltd
Not applicable
150
Beijing, Chongqing
2025-09-22
Recruiting
BioNTech SE
Phase 1/2
880
Baoding, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2025-09-22
Recruiting
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
NCT07154264Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugsBirelentinib·Venetoclax
Dizal Pharmaceuticals
Phase 2
66
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Yichang, Changsha, Changzhou
2025-09-22
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Bengbu, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin
2025-09-22
Not yet open
RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction
NCT07166380Transcranial Bone Marrow Injection, RK-4, Acute Large Hemispheric Infarction, Acute Ischemic Stroke
Neurodawn Pharmaceutical Co., Ltd.
Phase 1/2
18
Beijing
2025-09-20
Recruiting
Beijing Tiantan Hospital
Not applicable
750
Beijin, Beijing
2025-09-20
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 2
30
Baotou, Beijing, Guangzhou, Shenzhen
2025-09-19
Recruiting
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
NCT07170800Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
DrugDelamanid
WestVac Biopharma Co., Ltd.
Phase 2
60
Wuhan, Changsha, Nanjing, Jinan, Chengdu, Beijing, Shanghai
2025-09-19
Recruiting
InventisBio Co., Ltd
Phase 3
390
Beijing
2025-09-18
Recruiting
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 1
64
Beijing
2025-09-18
Recruiting
Peking University Cancer Hospital & Institute
Phase 2
30
Beijing
2025-09-18
Not yet open
Bing Han
Phase 2
3
Beijing
2025-09-18
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
40
Beijing
2025-09-18
Active, closed
Hoffmann-La Roche
Phase 3
1,101
Xuzhou, Shanghai, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-09-17
Recruiting
Sanofi
Phase 3
942
Baotou, Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian
2025-09-17
Recruiting
QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
NCT07049185Esophageal Squamous Cell Carcinoma
DrugLenvatinib
Peking University Cancer Hospital & Institute
Phase 2
35
Beijing
2025-09-17
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
80
Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing
2025-09-17
Recruiting
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
NCT07172204Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60
First Affiliated Hospital of Zhejiang University
Phase 2
25
Beijing, Shenzhen, Suzhou, Nanchang, Hangzhou
2025-09-16
Recruiting
Sanofi
Phase 3
942
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Hangzhou, Harbin
2025-09-16
Recruiting
A Clinical Study of GK02 in Malignant Ascites
NCT07378436Malignant Ascites Caused by Advanced Solid Tumors
Beijing Geekgene Technology Co., LTD
Early Phase 1
9
Beijing
2025-09-16
Recruiting
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
NCT07100067Relapsed/Refractory Multiple Myeloma(MM)
Nanjing Legend Biotech Co.
Not applicable
35
Beijing, Tianjin, Wuhan
2025-09-16
Recruiting
Beijing GoBroad Hospital
Not applicable
39
Beijing
2025-09-16
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
DrugEmpasiprubart
argenx
Phase 3
160
Fuzhou, Guangzhou, Beijing, Xi'an
2025-09-16
Recruiting
Beijing Tiantan Hospital
Not applicable
384
Beijing
2025-09-15
Not yet open
Peking Union Medical College Hospital
Observational
6,743
Beijing
2025-09-15
Recruiting
Shanghai Henlius Biotech
Phase 2
60
Beijing, Jinan
2025-09-15
Recruiting
Shanghai Henlius Biotech
Phase 2
60
Beijing
2025-09-15
Recruiting
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Phase 1
12
Beijing
2025-09-15
Recruiting
TaVNS for Acute Intracerebral Hemorrhage
NCT06918964Intracerebral Hemorrhage
Beijing Tiantan Hospital
Not applicable
186
Beijing
2025-09-15
Active, closed
Eli Lilly and Company
Phase 3
800
Baotou, Beijing, Chongqing, Harbin, Hefei, Jinan, Luoyang, Nanjing
2025-09-15
Not yet open
Prime Gene Therapeutics Co., Ltd.
Phase 3
600
Beijing, Lanzhou, Baoding, Cangzhou, Langfang, Shijiazhuang, Daqing, Harbin
2025-09-15
Not yet open
Acupuncture for Anxiety/Depression in Patients With Breast Cancer
NCT07183813Anxiety Depression, Breast Cancer, Acupuncture
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
360
Beijing
2025-09-15
Recruiting
A Phase I Study of CREPT-618 in Locally Advanced HCC
NCT07364357Hepatocellular Carcinoma (HCC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
13
Beijing
2025-09-15
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
544
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Quanzhou, Xiamen, Zhangzhou
2025-09-15
Recruiting
A Cohort Study on Increasing Blood Pressure Benefits in Sleep Apnea Patients After CPAP Treatment
NCT07357272Hypertension (HTN), Sleep Apnea Syndrome, Obstructive
Beijing Anzhen Hospital
Observational
200
Beijing
2025-09-15
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
414
Beijing, Chengdu, Guangzhou, Hangzhou, Luoyang, Macau, Nanchang, Shanghai
2025-09-13
Recruiting
Chinese PLA General Hospital
Observational
150
Beijing
2025-09-12
Active, closed
Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma
NCT07147361Esophageal Squamous Cell Carcinoma (ESCC), Cervical Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Head and Neck Squamous Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
800
Beijing
2025-09-12
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
382
Beijing
2025-09-12
Active, closed
ASKC200 for Knee Osteoarthritis Pain
NCT07742852Osteoarthritis (OA) of the Knee, Pain
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 2
175
Beijing
2025-09-12
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Hefei, Beijing, Fuzhou, Fyzhou, Xiamen, Lanzhou, Nanning, Harbin
2025-09-11
Recruiting
Janssen Research & Development, LLC
Phase 3
220
Beijing, Chengdu, Guangzhou, Nanjing, Ningbo, Tianjin, Wenzhou, Wuhan
2025-09-10
By invitation
Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma
NCT07520214Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Glioblastom WHO Grade 4
Beijing Neurosurgical Institute
Early Phase 1
9
Beijing
2025-09-10
Recruiting
Toll Biotech Co. Ltd. (Beijing)
Phase 2
24
Beijing
2025-09-10
Recruiting
Pfizer
Phase 3
140
Beijing, Guangzhou, Changsha, Shanghai, Chengdu, Hangzhou
2025-09-10
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 3
400
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Gannan, Nanchang
2025-09-10
Recruiting
Shanghai JMT-Bio Inc.
Phase 1/2
48
Beijing
2025-09-09
Recruiting
Bristol-Myers Squibb
Phase 2
182
Beijing, Xiamen, Nanning, Nanchang, Jinan, Linyi, Hangzhou, Linhai
2025-09-09
Recruiting
Chipscreen Biosciences, Ltd.
Phase 1/2
220
Beijing, Chengde, Shijiazhuang, Shiyan, Jinan, Taiyuan, Xi’an, Hangzhou
2025-09-08
Recruiting
Peking University Sixth Hospital
Not applicable
62
Beijing
2025-09-08
Recruiting
Guangdong Provincial People's Hospital
Not applicable
96
Beijing, Longyan, Zhangzhou, Guangzhou, Meizhou, Shantou, Shaoguan, Zhongshan
2025-09-08
Active, closed
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
Phase 2
30
Beijing
2025-09-08
Recruiting
TCM as an Adjuvant Treatment in Mycobacterium Abscessus Pulmonary Disease
NCT07295938Mycobacterium Abscessus Pulmonary Disease
Shanghai University of Traditional Chinese Medicine
Phase 2
352
Beijing, Guangdong, Hefei, Nanchang, Shanghai
2025-09-08
Not yet open
CPET-based HIIT for MAFLD
NCT07177963Metabolic Dysfunction-Associated Fatty Liver Disease
Tang Yida
Not applicable
54
Beijing
2025-09-08
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 3
602
Beijing
2025-09-08
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Beijing, Binhai, Changchun, Changsha, Chengdu, Chenzhou, Chifeng, Chongqing
2025-09-06
By invitation
Beijing Chao Yang Hospital
Not applicable
228
Beijing
2025-09-05
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
280
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Nanjing, Changchun, Jinan
2025-09-05
Recruiting
Beijing Tiantan Hospital
Not applicable
674
Beijing
2025-09-05
Recruiting
Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
NCT07148791IgG4 Related Disease, B-cell Mediated Autoimmune Disorders
Chinese PLA General Hospital
Phase 2
9
Beijing
2025-09-05
Recruiting
BeOne Medicines
Phase 3
500
Beijing, Fuzhou, Lanzhou, Guangzhou, Jiangmen, Nanning, Guiyang, Shijiazhuang
2025-09-04
Active, closed
Capital Medical University
Not applicable
438
Ma’anshan, Beijing, Zhangzhou, Heyuan, Qinzhou, Baoding, Harbin, Jiamusi
2025-09-04
Recruiting
Ausper Biopharma Co., Ltd.
Phase 2
200
Beijing, Jilin City, Chongqing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou
2025-09-04
Recruiting
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
NCT07215663Systemic Lupus Erythematosus (SLE)
DrugCizutamig
Candid Therapeutics
Phase 1
47
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-09-04
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 3
504
Beijing
2025-09-04
Recruiting
Sunshine Lake Pharma Co., Ltd.
Phase 1
96
Beijing
2025-09-03
Recruiting
DIND in Patients With aSAH : Real World Study
NCT07160088Aneurysmal Subarachnoid Hemorrhage (aSAH)
Xuanwu Hospital, Beijing
Observational
10,000
Beijing
2025-09-03
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2025-09-02
Active, closed
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
209
Hefei, Beijing, Sichuan, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zunyi
2025-09-02
Active, closed
Servier (Tianjin) Pharmaceutical Co. LTD.
Not applicable
62
Beijing, Qionghai, Chengdu
2025-09-02
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Nanning, Nantong
2025-09-02
Recruiting
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase 1/2
42
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhuhai, Nanning, Jinan
2025-09-02
Recruiting
Clinical Multimodal Surveillance of Respiratory Syndrome Pathogens
NCT07694648Respiratory Tract Infections (RTI), Respiratory Syndrome, Acute, Severe, Acute Respiratory Infections (ARIs)
Huashan Hospital
Observational
2,398
Beijing, Guangzhou, Zhuhai, Shijiazhuang, Harbin, Jiamusi, Shangqiu, Zhengzhou
2025-09-01
Not yet open
Capital Medical University
Observational
35
Beijing
2025-09-01
By invitation
TACE Treats Nodular Goiter
NCT07258199Nodular Goiter
Peking Union Medical College Hospital
Not applicable
30
Beijing
2025-09-01
Recruiting
Daihong Liu
Phase 2
10
Beijing
2025-09-01
Not yet open
Shanghai Chest Hospital
Not applicable
465
Beijing, Zhengzhou, Nanjing, Ningbo, Shanghai
2025-09-01
Active, closed
Chinese PLA General Hospital
Observational
1,265
Beijing
2025-09-01
Recruiting
Peking University People's Hospital
Observational
100
Beijing
2025-09-01
Not yet open
Zhejiang Teruisi Pharmaceutical Inc.
Phase 1/2
66
Beijing
2025-09-01
Recruiting
China-Japan Friendship Hospital
Observational
12,000
Beijing
2025-09-01
Recruiting
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
148
Beijing
2025-09-01
Recruiting
Chinese PLA General Hospital
Phase 2
204
Beijing
2025-09-01
Not yet open
Phrenic Nerve Stimulation for Reducing Ventilation Duration in Acute Cerebral Infarction: A Multicenter Randomized Controlled Trial
NCT07133932Cerebral Infarction, Mechanical Ventilation, Acute Cerebrovascular Accident, Adult
Xuanwu Hospital, Beijing
Not applicable
590
Beijing, Shijiazhuang
2025-09-01
Not yet open
A Study on Cardiopulmonary Exercise Tolerance Standards for Healthy Chinese Population
NCT07108296Oxygen Consumption, Cardiorespiratory Fitness
Affiliated Hospital of Changchun University of Chinese Medicine
Observational
4,620
Beijing, Quanzhou, Guangzhou, Nanning, Daqing, Harbin, Puyang, Zhengzhou
2025-09-01
Recruiting
China-Japan Friendship Hospital
Early Phase 1
40
Beijing
2025-09-01
Recruiting
Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease
NCT07068438Chronic Bronchitis, COPD (Chronic Obstructive Pulmonary Disease)
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
210
Hefei, Beijing, Changzhou, Suzhou, Wuxi, Xuzhou, Nanchang, Hangzhou
2025-09-01
Recruiting
Validation of RCC Predicting Model With Emulated-target Trial
NCT07117227Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Tumor Thrombus, Prognosis
Peking University Third Hospital
Observational
4,700
Beijing
2025-09-01
Recruiting
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
NCT07653659Distributive Shock, Hemodynamic Assessment, Critical Illness
Peking Union Medical College Hospital
Observational
30
Beijing
2025-09-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
10
Beijing
2025-09-01
Recruiting
Peking Union Medical College Hospital
Observational
50
Beijing
2025-09-01
Recruiting
UBT251 Injection Phase II Clinical Study (CKD)
NCT07134335Obesity &Amp; Overweight, Chronic Kidney Disease
DrugUBT251
The United Bio-Technology (Hengqin) Co., Ltd.
Phase 2
180
Beijing
2025-09-01
Not yet open
Xuanwu Hospital, Beijing
Observational
700
Beijing
2025-09-01
Not yet open
China-Japan Friendship Hospital
Not applicable
105
Beijing
2025-09-01
Recruiting
Artificial Intelligence Used in Screening Adrenal Nodules
NCT07198152Adrenal Incidentalomas, Thoracic CT-scan
Peking University First Hospital
Observational
600
Beijing
2025-09-01
Active, closed
Beijing Friendship Hospital
Observational
380,000
Beijing
2025-09-01
Active, closed
Mi Chen
Observational
1,500
Beijing
2025-09-01
Recruiting
Xuanwu Hospital, Beijing
Not applicable
80
Beijing
2025-09-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
180
Beijing
2025-09
Not yet open
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
153
Beijing
2025-09
Not yet open
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
75
Beijing
2025-09
Not yet open
A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.
NCT06886139CD20-positive Diffuse Large B-Cell Lymphoma
DrugTRS005
Zhejiang Teruisi Pharmaceutical Inc.
Phase 2
139
Beijing
2025-09
Not yet open
Enhanced Recovery After Surgery (ERAS) Pathway in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy
NCT05576766Prostate Cancer, Robot-Assisted Laparoscopic Radical Prostatectomy, Enhanced Recovery After Surgery (ERAS) Protocol, Prehabilitation
Peking University First Hospital
Not applicable
54
Beijing
2025-09
Rows per page Showing 1501–2000 of 5576
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=4

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,576 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,389 of the 5,576 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 990 have not yet opened recruitment, 1,019 are active but closed to new participants, and 178 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.